18:24 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
23:29 , Nov 7, 2018 |  BC Extra  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
23:24 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S....
22:03 , Nov 2, 2018 |  BioCentury  |  Politics, Policy & Law

Clear and present danger

The biopharma industry is distracted by so many false alarms and exaggerated predictions of doom that its leaders have become desensitized to a real and imminent danger. Limitations on immigration and travel will undermine scientific...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Lilly is Dicerna's second RNAi partner within a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) on Oct. 29 to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna...
10:02 , Oct 29, 2018 |  BC Extra  |  Company News

Lilly is Dicerna's second RNAi partner in a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna has made within...
23:15 , Oct 26, 2018 |  BioCentury  |  Product Development

R&D merry-go-round

An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition...
17:13 , Oct 26, 2018 |  BC Week In Review  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
23:07 , Oct 24, 2018 |  BC Extra  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
01:55 , Oct 13, 2018 |  BioCentury  |  Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...